• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Pliant Therapeutics Inc (NQ: PLRX )

    15.73 +0.83 (+5.57%)
    Streaming Delayed Price Updated: 1:35 PM EST, Nov 6, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Pliant Therapeutics Inc

    < Previous 1 2 3 4 5 6 7 Next >
    Pliant Therapeutics to Participate in the Stifel Healthcare Conference
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    Pliant Therapeutics INTEGRIS-PSC Phase 2a Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in a Late-Breaking Presentation at The Liver Meeting® 2024
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    Pliant Therapeutics Appoints Gary Palmer, M.D. as Senior Vice President of Medical Affairs
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    These Analysts Revise Their Forecasts On Pliant Therapeutics Following Q1 Earnings
    Via Benzinga
    Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer
    From Aligos Therapeutics
    Via GlobeNewswire
    Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Respiratory Society International Congress 2024
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    Pliant Therapeutics to Participate in Upcoming Investor Events
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    Pliant Therapeutics Announces Four Upcoming Presentations at the European Respiratory Society International Congress 2024
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    PLRX Stock Earnings: Pliant Therapeutics Misses EPS for Q2 2024
    PLRX stock results show that Pliant Therapeutics missed analyst estimates for earnings per share the second quarter of 2024. 
    Via InvestorPlace
    Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    Pliant Therapeutics to Participate in the Canaccord Genuity 44th Annual Growth Conference
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-PSC Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Continued Antifibrotic and Anti-Cholestatic Activity Displayed Across Multiple Measures
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    7 Biotech Stocks to Buy on the Dip: June 2024
    With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation. 
    Via InvestorPlace
    Pliant Therapeutics Announces Appointment of Steve Krognes to Board of Directors
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress™
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    Pliant Therapeutics' Drug Trial Shows Promise In Reversing Lung Fibrosis In Patients
    Phase 2a trial results of Pliant Therapeutics' bexotegrast (PLN-74809) for idiopathic pulmonary fibrosis. Reduced lung collagen, improved FVC, and cough severity, signaling potential fibrosis... 
    Via Benzinga
    Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    Pliant Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver International Liver Congress™
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    PLRX Stock Earnings: Pliant Therapeutics Misses EPS for Q1 2024
    PLRX stock results show that Pliant Therapeutics missed analyst estimates for earnings per share the first quarter of 2024. 
    Via InvestorPlace
    Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    Pliant Therapeutics to Participate in Upcoming Investor Events
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    Pliant Therapeutics to Participate in Upcoming Investor Events
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    Pliant Therapeutics to Participate in Upcoming Investor Conferences
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    Pliant Therapeutics to Participate in Upcoming Investor Events
    From Pliant Therapeutics, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.